Tocilizumab (Anti-Human IL6R) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R, thereby inhibiting both classical and trans signaling. Tocilizumab can be used in research on rheumatoid arthritis, systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA).

Method: Ba/F3-gp130-IL-6R cells were incubated with Tocilizumab at concentrations ranging from 0.001 to 10000 μg/mL for 2 days, followed by cell cytotoxicity assay.
Result: Tocilizumab could inhibit cell proliferation, with an IC₅₀ value of 13.5 ng/mL. ^[1]
Method: Human-derived HARA-B cells were incubated with Tocilizumab at concentrations of 1, 10, 100 ng/mL for 24h and 48 h, followed by cell proliferation assay.
Result: Tocilizumab inhibited the cell proliferation (growth rate) in a dose-dependent manner, growth rate by HACM was reduced almost completely by 100 ng/mL tocilizumab.^[2]
Method: SAS cells were incubated with tocilizumab at concentrations of 1 μM and 1–5 μM for 6 h and 24 h, respectively, followed by Western blot analysis and RT-PCR.
Result: Tocilizumab reduced STAT3 phosphorylation in SAS cells in vitro, consistent with the findings observed in vivo, and decreased VEGF mRNA expression in SAS cells cultured in serum-free medium. ^[3]

Method: HARA-B cells were inoculated into the left ventricle of nude mouse hearts. Three weeks after inoculation, Tocilizumab (Anti-Human IL6R) was intravenously injected weekly for the next three weeks (1.0 mg/100 μL, once every two weeks for three weeks).
Result: The volume of each metastatic lesion in the brains of mice injected with Tocilizumab (Anti-Human IL6R) was significantly smaller. ^[2]
Method: SCID mice bearing SAS cells received intraperitoneal injection of tocilizumab at a dose of 100 μg/mL every 48 hours for 20 days.
Result: Tocilizumab suppresses OSCC progression and suppresses tumor angiogenesis.^[3]

Objective: To validate that IL-6 signaling is essential for TAM (tumor-associated macrophages)-enhanced CSC (cancer stem cells) function. Concentrations: 5 μg/ml. Incubation Time: 72 h. Method: For co-culture experiments, 12-well Transwell chambers were used with 2×105 HepG2 or Hep3B cells seeded in the lower chamber one day before co-culture and either 5×105 or 1×106 TAMs added in the upper chamber. Tocilizumab or human IgG antibody were added in indicated experiments to selected wells. After 24 to 72 hours, HCC cells and CD14+ TAM cells were collected separately for analysis. Cells:HepG2 cell lines, TAMs isolated from HCCs (hepatocellular carcinoma)

Human

Immobilized Human IL-6R alpha/CD126 Protein (His) (TMPY-00864) at 1 μg/mL (100 μL/well) can bind Tocilizumab. The EC50 is 2.610 ng/mL.

Monoclonal

Unconjugated